Sabra Health Care REIT stock gets a fresh valuation review

Published on 10/08/2026 at 03:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sabra Health Care REIT stock carries a USD 22.79 fair value from October 4. Q2 same-store revenue rose 8.6 percent, while EPS missed consensus.

SBRA, US78573L1061, Illustration mit AI erstellt.

Sabra Health Care REIT (ISIN US78573L1061) received a fresh valuation review on October 4, 2026, with fair value set at USD 22.79. Simply Wall St said the revised thesis places greater weight on managed senior housing operations, portfolio recycling and balance-sheet flexibility.

SHOP growth changes the story

The October 4 update highlighted 8.6 percent same-store revenue growth and 13.7 percent cash NOI growth in Q2 2026. It also cited USD 9 million of annualized NOI gains from Avamere rent resets, giving the operating picture a more specific basis than demographic demand alone.

The valuation work kept fair value at USD 22.79, while the discount rate moved from 7.85 percent to 7.87 percent and the future P/E assumption moved from 32.14 times to 32.25 times, according to Simply Wall St.

Revenue beat, earnings missed

Sabra reported USD 230.11 million of Q2 2026 revenue, an increase of 24.7 percent from the year-earlier quarter, while adjusted EPS was negative USD 0.10 against a USD 0.17 consensus estimate, MarketBeat reported. The contrast matters for a healthcare REIT because higher property revenue did not translate into a positive quarterly per-share result.

MarketBeat also reported a Moderate Buy consensus from 14 analysts, with seven Buy ratings, seven Hold ratings and an average price target of USD 22.23. That target lies 18.6 percent above the USD 18.74 Nasdaq price, a wider gap than the operating update alone would imply.

Dividend income meets balance-sheet risk

Sabra's investor-relations page describes a healthcare property portfolio spanning the United States and Canada and lists USD 7.4 billion of enterprise value and USD 1.3 billion of liquidity. The company also identifies a balanced capital structure and long-term healthcare real estate demand as central operating priorities.

The October 4 analysis identified a USD 102.4 million loan-loss reserve as a pressure point alongside the funding needs of a managed senior housing pipeline. That counterweight leaves operating growth and capital flexibility as the two figures most relevant to the valuation discussion.

SBRA stock stays below its yearly high

SBRA was last at USD 18.74 on Nasdaq on October 7, 2026, down 1.99 percent from the prior close. The 52-week range was USD 17.17 to USD 22.77, while market capitalization stood at USD 4.7 billion and volume reached 2,176,635 shares.